References

1. Stoddard MF, Pawking PR, Prince CK, and Ammash NM, et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiography study. JACC 1995;25:452-459.

2. Weigner N, Caulfield TA, Danias PG, Silverman DJ, and Manning WJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997;126:615-620.

3. Botto GL et al. Atrial mechanical function after conversion of recent onset atrial fibrillation to sinus rhythm. PACE 1998;21:813 part II.

4. Abi-Samra F, et al. Would a stricter regimen of anticoagulation be effective in further reducing the risk of thromboembolic events following electrical cardioversion for atrial fibrillation? PACE 1998;21:930 Part II.

5. Manning WJ, Silverman DI, Keighley CS, Oettgen P, and Douglas PS. Transesophageal echocardio-graphically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5 year study. JACC 1995;25:1354-1361.

5a. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF. The Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. N Engl J Med 2001;344:1411-1420.

6. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Trans-esophageal Echocardiography Correlates of Thromboembolism in High-Risk Patients with Nonvalvu-lar Atrial Fibrillation. Ann Intern Med 1998;128:639-647.

7. Petersen P et al. Placebo controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175-178.

8. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991;84:527-539.

9. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators (BAATAF). The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.

10. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, and Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. JACC 1991;18:349-355.

11. Ezekowitz MD. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-1412.

12. Investigators of 5 studies. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994;154:1449-1457.

13. The SPAF III Writing Committee. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin. JAMA 1998;279:1273-1279.

14. Singer DE, Hughes RA, Gregg DR, Sheehan MA, Oertel LB, Meraventano SW, et al. The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: the BAATAF study. Am Heart J 1992;124:1567-1573.

15. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism^ atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994;343:687-691.

16. Black IW, et al. Thromboembolic risk of atrial flutter. JACC 1992;19:314A.

17. Irani WN, Brayburn PA, Afridi L. Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial Flutter. Circulation 1997;95:962-966.

18. Seidl K, Haper B, Schwick NG, Zellneu D, Zahn K, and Senges J. Risk of thromboembolic events in patients with atrial flutter. Am J Cardiol 1998;82:580-583.

19. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic Therapy in Atrial Fibrillation. Chest 2001;119:194S-206S.

20. Fenelon G, Wijns W, Andries E, and Brugada P. Tachycardiomyopathy: Mechanisms and Clinical Implications. PACE 1996;19:95-106.

21. Packer DL, Bardy GH, Worley SJ, Smith MS, Cobb FR, Coleman RE, et al. Tachycardia-induced cardiomyopathy: a reversible left ventricular dysfunction. Am J Cardiol 1986;57:563-570.

22. Blitzer M. Rhythm management in atrial fibrillation—with a primary emphasis on pharmacological therapy. Part 1. PACE 1998;21:590-602.

23. Channer KS, James MA, MacConnell T, and Kees JR. Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity. Br J Clin Pharmacol 1994;37:53-57.

24. Philips BG. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. Pharmacotherapy 1997;17(6):1238-1245.

25. Grant AO. Mechanisms of atrial fibrillation and action of drugs used in its management. Am J Cardiol 1998;82:43N-49N.

26. Heywood JT, Graham B, Marais GE, and Jutzy KR. Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure. Am J Cardiol 1991;67:1150-1152.

27. Goldenberg IF, Lewis WR, Dias VC, Heywood JT, and Pedersen WK. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol 1994;74:884-889.

28. Kumar A. Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. South Med J 1996;89:779-785.

29. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, and Woosley RL. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. Eur Heart J 1995;16:521-528.

30. Roth A, Kaluski E, Felner S, Heller K, and Lanindo S. Clonidine for patients with rapid/atrial fibrillation. Ann Intern Med 1992;116:388-390.

31. Scardi S, Humar F, Pandullo C, and Poletti A. Oral clonidine for heart rate control in chronic atrial fibrillation. Lancet 1993;341:1211-1212.

32. The Cardiac Arrhythmia Suppression Trial Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-413.

33. Coplen SE, Antman EM, Berlin JA, Hewitt P, and Chalmas TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. Circulation 1990;82:1106-1116.

34. Stroke Prevention in Atrial Fibrillation Investigators. Preliminary report of the stroke prevention in atrial fibrillation study. N Engl J Med 1990;322:863-868.

35. Antman EM. Maintaining sinus rhythm with antifibrillatory drugs in atrial fibrillation. Am J Cardiol 1996;78:67-72.

36. Flaker GC, Blackshear JL, McBride R, Kuonmal RA, Halperin JL, and Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. JAC 1992;20:527-532.

37. Sir Thomas Lewis, in Diseases of the Heart, Macmillan and Co., 1933, 1st ed., p. 90.

37a. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. Atrial fibrillation follow-up investigation of rhythm management—the AFFIRM study design. Am J Cardiol 1997;79:1198-1202.

38. Friedman PL and Stevenson WG. Proarrhythmia. Am J Cardiol 1998;82:50N-58N.

39. Reiffel JA. Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter. Am Heart J 1998;135:551-556.

40. Boriani G, Biffi M, Capucci A, Botto GL, Brottoni T, Rubino J, et al. Oral loading with propafenone: a placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation. PACE 1998;21:2465-2469.

41. Boriani G, Biffi M, Capucci A, Botto G, Brottoni T, Ongari M, et al. Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. PACE 1998;21:2470-2474.

42. Kochiadakis GE, Egaumenidis NE, Simantirakis EN, Marketov ME, Vorthenakis FJ, Mezilis NE, et al. Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study. PACE 1998;21:2475-2479.

43. Botto GL, Bonini W, Brottoni T, Espureo M, Cappelletti G, Lombardi R, et al. Randomized, crossover, controlled comparison of oral loading versus intravenous infusion of propafenone in recent-onset atrial fibrillation. PACE 1998;21:2480-2484.

44. Crijns HJ, Gosselink AT, and Lie KI. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. Cardiovasc Drugs Ther 1996;10:145-152.

45. Chimienti M, Cullen MT Jr., and Casadei G. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Eur Heart J 1995; 16:1943-1951.

46. Azpitarte J, Alvarez M, Baun O, Garcia R, Moreno E, Martin F, et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Eur Heart J 1997;18:1649-1654.

47. Steinbeck G, RempT, and Hoffmann E. Effects of class I drugs on atrial fibrillation. JCE 1998;9:S104-S108.

48. Costeas C, Kassotis J, Blitzer M, and Keiffel JA. Rhythm management in atrial fibrillation—with a primary emphasis on pharmacological therapy: part 2. PACE 1998;21:742-752.

49. Kassotis J, Costens C, Blitzer M, and Keiffel JA. Rhythm management in atrial fibrillation—with a primary emphasis on pharmacologic therapy: part 3. PACE 1998;21:1133-1145.

50. Hopson JR, Buxton AE, Rinkenberger RL, Nademanee K, Heilman JM, and Kienzle MG. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. Am J Cardiol 1996;77:72A-82A.

51. Chimienti M, Cullen MT Jr., and Casadei G. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the flecainide and propafenone Italian study investigators. Am J Cardiol 1996;77:60A-75A.

52. Aliot E and Penjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital outpatients with symptomatic paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996;77:66A-71A.

53. Boriani G, Biffi M, Capucci A, Botto GL, Brottoni T, Rubino I, et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. Annals Int Med 1997;126:621-625.

54. Lee SH, Chen SA, Tai CT, Chiang CE, Wen ZE, Chen YJ, et al. Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am J Cardiol 1997;79:905-908.

55. Kochiadakis GE, Isoumenidis NE, Marketov ME, Solomon ML, Kanoupakis EM, and Vardas, PE. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1998;81:995-998.

56. Reisinger J, Gattevev E, Heinze G, Wiesinger K, Zeindlhofer E, Gottermeier M, et al. Prospective comparison of flecamide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998;81:1450-1454.

57. Bianconi L and Mennuni M. Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. Am J Cardiol 1998;82:584-588.

58. Donovan KD, Power BM, Hockings BE, Dobb GJ, and Lee KY. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol 1995;75:693-697.

59. Sung RJ, Tan HL, Karagounis L, Honyok JJ, Falk R, Platia E, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Am Heart J 1995;129:739-748.

60. Naccarelli GV, Dorian P, Hohnloser SH, and Coumel P. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996;77:53A-59A.

61. Ferreira E, Sunderji R, and Gin K. Is oral sotalol effective in converting atrial fibrillation to sinus rhythm?. Pharmacotherapy 1997;17:1233-1237.

62. Galve E, Rius T, Ballester R, Artazn MA, Arnau JM, Garcia-Vovado P, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized controlled study. JACC 1996; 27:1079-1082.

63. Kochiadakis GE, Joumenidis NE, Solomov MC, Kaleboubas MD, Chlouverakis GJ, and Vardas PE. Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am J Cardiol 1999;83:58-61.

64. Kochiadakis GE, Joumenidis NE, Solomov MC, Kaleboubas MD, Chlouverakis GJ, and Vardas PE. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. JACC 1999;33:966-971.

65. Tieleman RG, Gosselink AT, Crijns HJ, van Gelder JC, Van den Berg MP, de Kom PJ et al. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997;79:53-57.

66. Derin NZ et al. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Arch Intern Med 1996;156:49-53.

67. Reimold SC, Maisel WH, and Antman EM. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis. Am J Cardiol 1998;82:66N-71N.

68. Rae AP. Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. Am J Cardiol 1998;82:59N-65N.

69. Ganau G and Lenzi T. Intravenous propafenone for converting recent onset atrial fibrillation in emergency departments: a randomized placebo-controlled multicenter trial. J Emerg Med 1998;16:383-387.

70. Kochiadakis GE, Igoumenidis NE, Solomov MC, Partheunkis FJ, Christakis-Hampsis MG, Chlover-akis GJ, et al. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion. Cardiovasc Drugs Ther 1998;12:75-81.

71. Volgman AS, Corberry PA, Stambler B, Lewis WR, Dunn GH, Perry KT, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. JACC 1998;31:1414-1419.

72. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, and VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-1621.

73. Stambler BS, Wood MA, and Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation. Circulation 1997;96:4298-4306.

74. Vos MA, Golitsyn SR, Staugl K, Kudn MY, Van Wijk LV, Harry JD, et al. Superiority of ibutilide (anew class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. Heart 1998;79:568-575.

75. Lovecchio F, Berlin R, Brubacher JR, and Sholer JB. Hypertonic sodium bicarbonate in an acute flecainide overdose. Am J Emerg Med 1998;16:534-537.

76. Kerns W, English B, and Food M. Propafenone overdose. Ann Emerg Med 1994;24:98-103.

77. Obel OA and Camm AJ. The use of drugs for cardioversion of recent onset atrial fibrillation and flutter. Drugs Aging 1998;12:461-476.

78. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, and Curiel R. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-498.

79. Cairns JA, Connolly SJ, Roberts R, and Gent M. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997;349:675-682.

80. Julian DG, Camm AJ, Fraugin G, Jruse MJ, Munoz A, Schwartz PJ, and Simon P. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-674.

81. The CASCADE Investigators. Randomized Antiarrhythmic Drug Therapy in Survivors of Cardiac Arrest. Am J Cardiol 1993;72:280-287.

82. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997;350:1417-1424.

82a. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrences of atrial fibrillation. N Engl J Med 2000;342:913-920.

83. Jafari-Fesharaki M, et al. Adverse effects of amiodarone. PACE 1998;21:108-120.

84. Julian DG, Prescott RJ, Jackson FS, et al. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;1:1142-1147.

85. Waldo AL, Camm JA, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.

86. Reiffel JA. Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. Am J Cardiol 1998;82:72N-81N.

87. The DIAMOND Study Group. Dofetilde in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Clin Cardiol 1997;20:704-710.

88. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999;341:857-865.

88a.Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Beck M, Billing CB, Jr. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: The symptomatic atrial fibrillation investigative (SAFIRE-D) study. Circulation 2000;102:2385-90.

89. Falk RH, Pollak KA, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. JACC 1997;29:385-390.

90. Teichman SL, Fisher JD, Matus JA, and Kim SG. Disopyramide-pyridostigmine: report of a beneficial drug interaction. J Cardiovasc Pharmacol 1985;7:108-113.

91. Teichman SL, Ferrick A, Kim SG, Matus JA, Wasje LE, and Fisher JD. Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect. JACC 1987;10:633-641.

92. Jung W, Manz M, and Luderitz B. Effects of antiarrhythmic drugs on defibrillation threshold in patients with the implantable cardioverter defibrillator. PACE 1992;15:645-648.

93. Oral H, Souza JJ, Michaud GF, Knight BP, Goya IR, Strickberger SA, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999;340:1849-1854.

94. Lau CP and Lok NS. A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold. PACE 1997;20:2442-2452.

95. Opolski G, Stanislawska J, Gorecki A, Swiecicka G, Toubicki A, and Kroska T. Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion. Clin Cardiol 1997;20:337-340.

96. Prystowsky EN, Benson DW Jr., Fuster V, Hart KG, Kay GN, Myerburg RJ, et al. Management of patients with atrial fibrillation. Circulation 1996;93:1262-1277.

97. Channer KS, James MA, MacConnell T, and Kees JB. Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity. Br J Pharmacol 1994;37:53-57.

98. Almassi GH, Schowalter T, Nicolosi AC, Aggarwal A, Moritz TE, Henderson WG, et al. Atrial fibrillation after cardiac surgery. Ann Surg 1997;226:501-513.

99. Kowey PR, Taylor JE, Kinls SJ, and Mariuchok RA. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol 1992;69:963-965.

100. Andrews TC, Reimold SC, Berlin JA, and Antman EM. Prevention of supraventricular arrhythmias after coronary artery bypass surgery. Circulation 1991;84:III-236-III-244 (Suppl).

101. ParikkaH, ToivonenL, HeikkilaL, Vivtanen K, and Jnvinen A. Comparison of sotalol and metoprolol in the prevention of atrial fibrillation after coronary artery bypass surgery. J Cardiovasc Pharmacol 1998;31:67-73.

102. Gomes JA, Ip J, Santoni-Rugiv F, Mehta D, Evgin A, Lansman S, et al. Oral d,l-sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. JACC 1999;34:334-339.

103. Guarnieri T, Nolan S, Gottlieb SO, Dudek A, and Lowry DR. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the amiodarone reduction in coronary heart (ARCH) trial. JACC 1999;34:343-347.

104. Daoud EG, Strickberger SA, Man KC, Goyal R, Deeb GM, Bolling SF, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997;337:1785-1791.

105. Brode SE, Schwartzman D, Cattans DJ, Gottlieb CD, and Marchlinski FE. ICD-antiarrhythmic drug and ICD-pacemaker interactions. Cardiovasc Electrophysiol 1997;8:830-842.

Was this article helpful?

0 0
Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook


Post a comment